[HTML][HTML] Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human …
TA Westra, I Stirbu-Wagner, S Dorsman… - BMC Infectious …, 2013 - Springer
Background Infection with HPV 16 and 18, the major causative agents of cervical cancer,
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
TD Szucs, N Largeron, KJ Dedes, R Rafia… - … medical research and …, 2008 - Taylor & Francis
Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the …
RM Rogoza, TA Westra, N Ferko, JJ Tamminga… - Vaccine, 2009 - Elsevier
Cervical cancer is one of the most prevalent cancers among women worldwide.
Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and …
Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and …
The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands
JA Bogaards, VMH Coupé, CJLM Meijer, J Berkhof - Vaccine, 2011 - Elsevier
BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …
approved for women from age 12 to 25 years, but those older than 16 years receive no …
Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
IMCM de Kok, JDF Habbema, J van Rosmalen… - European journal of …, 2011 - Elsevier
Besides cervical cancer, the human papillomavirus (HPV) is found in other cancers and may
be preventable with HPV vaccination. However, these other cancers are often not accounted …
be preventable with HPV vaccination. However, these other cancers are often not accounted …
Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany
P Hillemanns, KU Petry, N Largeron, R McAllister… - Journal of Public …, 2009 - Springer
Aim Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …
A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France
X Bresse, M Adam, N Largeron, S Roze… - Human Vaccines & …, 2013 - Taylor & Francis
The aim was to compare the epidemiological and economic impact of 16/18 bivalent and
6/11/16/18 quadrivalent HPV vaccination in France, considering differences in licensed …
6/11/16/18 quadrivalent HPV vaccination in France, considering differences in licensed …
Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles
OBJECTIVES: Two human papillomavirus (HPV) vaccines are currently available: a bivalent
HPV-16/18 and a quadrivalent HPV-6/11/16/18 vaccine. The vaccines may have different …
HPV-16/18 and a quadrivalent HPV-6/11/16/18 vaccine. The vaccines may have different …
[HTML][HTML] A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
N Demarteau, B Detournay, B Tehard… - International journal of …, 2011 - Springer
Objective This study aimed at evaluating the cost-effectiveness of human papillomavirus
virus (HPV) vaccination in France, using a generally applicable succinct cohort model …
virus (HPV) vaccination in France, using a generally applicable succinct cohort model …
Cost–effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account
J Luttjeboer, TA Westra, JC Wilschut, HW Nijman… - Vaccine, 2013 - Elsevier
Despite an effective screening programme, 600–700 women are still diagnosed with
cervical cancer in the Netherlands each year. In 2009 a prophylactic vaccine against HPV …
cervical cancer in the Netherlands each year. In 2009 a prophylactic vaccine against HPV …
相关搜索
- cervical cancer genital warts
- cost effectiveness genital warts
- papillomavirus vaccination genital warts
- prevention of genital warts
- human papillomavirus situation in the netherlands
- hpv vaccines cost savings
- hpv vaccines epidemiological impact
- prophylactic vaccination situation in the netherlands
- hpv vaccines consequences evaluation
- cervical cancer cost effectiveness
- cervical cancer papillomavirus vaccination
- cervical cancer human papillomavirus
- cost effectiveness papillomavirus vaccination
- cost effectiveness human papillomavirus
- cost effectiveness hpv vaccine
- cost effectiveness hpv vaccination